Developmental Regulation of Prion Expression in Cattle and Mouse Embryonic Stem Cells

Oscar Alejandro Peralta Troncoso

Dissertation submitted to the faculty of the Virginia Polytechnic Institute and State University in partial fulfillment of the requirements for the degree of

Doctor of Philosophy

in

Biomedical and Veterinary Sciences

Willard H. Eyestone, Chairman

William R. Huckle

Ludeman A. Eng

Xiang-Jin Meng

Jill C. Sible

Mary Lynn Johnson

July 25th, 2008

Blacksburg, Virginia

Developmental Regulation of Prion Expression in Cattle and Mouse Embryonic Stem Cells

Oscar A. Peralta Troncoso

ABSTRACT

The host encoded cellular prion protein (PrP^C) is an N-linked glycoprotein tethered to the cell membrane by a glycophosphatidylinositol (GPI) anchor. Under certain conditions, PrP^C can undergo conversion into a conformationally-altered isoform (PrP^{Sc}) widely believed to be the pathogenic agent of transmissible spongiform encephalopathies (TSEs). Thus, tissues expressing PrP^C are potential sites for conversion of PrP^{Sc} during TSE pathogenesis. Although much is known about the role of PrP^{Sc} in prion diseases, the normal function of PrP^C is poorly understood. Lines of mice and cattle in which PrP^C has been ablated by gene knockout show no major phenotypical alterations other than resistance to TSE infection. However, recent reports using Prnp-null mouse models have suggested the participation of PrP^C in neural stem/progenitor cell proliferation and differentiation. The first objective in our study was to map the expression of PrP^C in twenty six somatic and reproductive tissues in ruminants. Our second objective was to characterize the ontogeny of PrP^C expression during bovine embryonic and early fetal development. Finally, we used a mouse embryonic stem cell (mESC) model to study the potential role of PrP^C during neurogenesis. In adult tissues, intense expression of PrP^C was detected in the central nervous system (CNS), thymus and testes, whereas the liver, striated muscle and female reproductive tissues showed the lowest expression. We observed that PrP^C was associated with tissues undergoing cellular differentiation including spermatogenesis, lymphocyte activation and hair follicle regeneration. Analyses in bovine embryos and fetuses indicated peaks in expression of PrP^C at days 4 and 18 post-fertilization, stages associated with the maternal-zygote transition and the maternal recognition of pregnancy and initiation of placental attachment, respectively. Later in development, PrP^C was expressed in the CNS where it was localized in mature neurons of the neuroepithelium and emerging neural trunks. Based on these observations, we hypothesized that PrP^C was involved in neurogenesis. We tested this hypothesis in a murine embryonic stem cell model (mESC). mESC were induced to form embryoid bodies (EBs) by placing them in suspension culture under differentiating conditions and allowed to differentiate *in vitro* for 20 days. We detected increasing levels of PrP^C starting on day 12 (8.21- fold higher vs. day 0; $P < 0.05$) and continuing until day 20 (20.77-fold higher vs. day 0; $P < 0.05$). PrP^C expression was negatively correlated with pluripotency marker Oct-4 (r= -0.85) confirming that mESC had indeed differentiated. To

provide a more robust system for assessing the role of PrP^C in neural differentiation, mESC were cultured with or without retinoic acid (RA) to encourage differentiation into neural lineages. Induction of EBs with retinoic acid (RA) resulted in an earlier up-regulation of PrP^C and nestin (day 12 vs. day 16; $P < 0.05$). In addition, immunofluorescence studies indicated co-expression of PrP^C and nestin in the same cells. The results of these experiments suggested a temporal link between PrP^C expression and expression of nestin, a marker of neural progenitor cells. We next tested whether PrP^C was involved in RA-enhanced neural differentiation from mESC using a PrP^C knockdown model. Plasmid vectors designed to express either a PrP-targeted shRNA or scrambled, control shRNA were transfected into mESC. Stable transfectants were selected under G418 and cloned. PrP-targeted and control shRNA clones, as well as wild-type mESC, were differentiated in presence of RA and sampled as above. PrP^C expression was knocked down in PrP-targeted shRNA cultures between days 12 and 20 (62.2 % average reduction vs. scrambled shRNA controls). Nestin expression was reduced at days 16 and 20 in PrP^C knockdown cells (61.3% and 70.7%, respectively vs. scrambled shRNA controls). These results provide evidence that PrP^C plays a role in the neural differentiation at a point up-stream from the stages at which nestin is expressed. In conclusion, the widely distributed expression of PrP^C in ruminant tissues suggests an important biological role for this protein. In the present work we have provided evidence for the participation of PrP^C in the differentiation of mESC along the neurogenic pathway.

ACKNOWLEDGMENTS

First, I would like to express my gratitude to my advisor Dr. Will Eyestone for his patience, encouragement and support in the completion of my doctorate degree. It was a great experience to work with Dr. Eyestone, he is a very enthusiastic and knowledgeable person, and an excellent scientist. I would also like to thanks my committee members Dr. William Huckle, Dr. Ludeman Eng, Dr. Xiang-Jin Meng, Dr. Jill Sible and the external examiner Dr. Mary Lynn Johnson for their guidance throughout this project. My gratitude to Kathy Lowe for her permanent and friendly support. I also would like to thanks the staff of the CREATE Lab for their assistance in my work.

This dissertation is dedicated to my wife Cecilia Zuleta, my parents Maria and Oscar, and my brothers Nicolas and Rodrigo. Their continue support and love made possible for me to achieve this degree. Thanks.

TABLE OF CONTENTS

LIST OF FIGURES

CHAPTER IV

CHAPTER V

INTRODUCTION

The complex nature of prions has intrigued the scientific community during the last 70 years. Since the first indication of scrapie infectivity in 1937 and the experimental transmission of the scrapie agent in sheep the same year, prions and their associated diseases, have been under constant investigation. Furthermore, the formulation of the prion hypothesis in 1966 and the discoveries by Prusiner in 1982, opened a completely new perspective in the understanding of these infectious proteins. One of the most interesting aspects of the prion hypothesis is the presence of a host-encoded isoform (PrP^C) with the autocatalytic or induced capacity to change its secondary configuration into a pathogenic isoform (PrP^{Sc}). Despite intense research undergoing during the last 20 years to probe this hypothesis, the most compelling evidence is yet to be reported. Another enigmatic aspect of the prion biology is the potential physiological function of PrP^C, a protein that is widely distributed in mammalian tissues and intensely expressed in the nervous system. PrP^C has been associated to several biological roles including cellular adhesion, signaling and protection. Recently, one study reported a positive association between PrP^C and differentiation of neural cells. These researchers argued that PrP^C was associated in a dose-dependent manner with differentiation of multipotent precursors into mature neurons *in vitro*. Moreover, analyses in mouse brain showed the PrP^C played a role in the proliferation of neural precursor cells.

In the present work, we described our efforts to better understand the potential function of PrP^C. In chapters two and three we mapped the expression of PrP^C in 30 different tissues of the bovine. These analyses characterized PrP^C as widely distributed protein expressed in organs with different physiological functions. This wide distribution and intense expression in neurons and lymphoreticular cells suggest that PrP^C may have an important physiological function. Chapter four focused on the developmental characterization of PrP^C during bovine embryogenesis. The stage-specific expression of PrP^C during pre-implantation stage suggests the participation of this protein in the early embryonic development. Thereafter analyses in fetuses showed an intense expression of PrP^C during the early development of the nervous system. This data led us to hypothesize a potential contribution of PrP^C in neurogenesis. This hypothesis was tested in the last chapter of this work. Analysis of PrP^C expression in mouse embryonic stem cell (mESC) showed a positive association between PrP^C expression and the marker for neural stem/progenitor cells, nestin. The final experiment demonstrated that the knockdown of PrP^C expression results in the significant reduction of nestin levels indicating a direct or indirect association between these proteins. This data represents evidence for the contribution of PrP^C in neurogenesis and support the reports of others indicating the participation of PrP^C as a neural differentiation factor.

1

CHAPTER I

PRION BIOLOGY AND BOVINE SPONGIFORM ENCEPHALOPATHY

INTRODUCTION

Transmissible spongiform encephalopathies (TSEs) are neurodegenerative, fatal diseases with no early diagnosis, treatment or cure (Collinge, 2001). Several species are affected by TSEs including human (Creutzfeldt-Jakob disease, Gerstmann-Straussler-Scheinker, Kuru, Fatal familial insomnia), bovine (spongiform encephalopathy), ovine (scrapie), deer (chronic wasting disease) and mink (transmissible encephalopathy). TSEs display a wide spectrum of clinical signs, neuropathology and epidemiology that result in difficult diagnosis and control. Despite their diverse presentations, all TSEs stem from the infectious, spontaneous or hereditary conversion of PrP^C into the pathogenic isoform PrP^{Sc} (Soto, 2006). The unpredictable properties of PrP^{Sc} and the potential zoonotic transmission of the bovine spongiform encephalopathy (BSE) have generated intense concern in the international community over animal product biosecurity. One of the most critical aspects of the TSE-infectious agent is the capacity to cross the species barrier from cattle to human through the consumption of beef products. Worldwide, 172 people have fallen victim to the variant CJD (vCJD) during 2008, and epidemiologists predict the presentation of more cases in the coming years due to existing pre-clinical or subclinical infection (Collee et al., 2006; NCJDSU, 2008). The first case of BSE was detected in USA in 2003, resulting in the ban of meat importation from USA to 53 countries with a drastic drop in 83% of the imports. Translated into economic terms, BSE produced a loss of 5 billion dollars which corresponded to 4% of the gross domestic agriculture product (Coffey et al., 2005).

The scientific community has been intrigued with the complex nature of prions for over 70 years. The first indication of prion infectivity was reported in 1937 in Scotland after immunization of sheep against louping ill. The vaccines used were accidentally elaborated from brain extracts obtained from animals infected with scrapie (Gordon, 1946). The fact that eight percent of the immunized animals developed scrapie, with the experimental transmission of the agent performed the same year, the infectious capacity of scrapie among sheep and goats was demonstrated (Cullie and Chele, 1939). In 1959, Hadlow suggested that Kuru, a neurodegenerative disease that affected New Guinea tribes might be similar to scrapie due to similarities in epidemiology, clinical signs and pathological findings. This hypothesis was later confirmed in 1965 by the successful transmission of Kuru to chimpanzees after incubation of 18 to 21 months (Gajdusek et al., 1965). One year later, Alper and colleagues reported that the molecular weight of the scrapie agent was significantly lower compared to a conventional virus (Alper et al., 1966). Moreover, Apler showed that the scrapie agent was able to resist doses of ultraviolet radiation (UV) sufficient to

inactivate nucleic acids. These experiments led to the formulation of the protein-only hypothesis, which described the scrapie agent as a particle conformed by a proteinaceous structure devoid of nucleic acids with the unique capacity to autoreplicate (Griffith, 1967). In the 1980s, Prusiner reported abundant experimental data in support of this hypothesis and proposed for the first time the term "prion" to describe the scrapie agent. Prion was defined as small proteinaceous infectious particle which was resistant to inactivation by most procedures that modify nucleic acids (Prusiner, 1982). This controversial suggestion supported the idea of a scrapie agent consisting only of an infectious protein and discredited the model that included a small nucleic acid in the core of the protein. Furthermore, one of the most intriguing aspects of the prion biology was the discovery of a host-encoded cellular prion protein or PrP^C (Oesch et al., 1985). This discovery guided to the formulation of the prion hypothesis that postulates that the agent responsible for prion propagation is originated by autocatalytic conversion of PrP^C into the pathogenic isoform. Physical contact between both isoforms induces instability of the PrP^C mainly α-helicoidal structure and results in its conversion into a predominantly β-sheet configuration characteristic of PrP^{Sc}.

Although the involvement of PrP^C in the infection of TSEs has been well documented, the function of PrP^C remains inconclusive. During the last decades, there have been several reports describing roles for PrP^C as an antioxidant, cytoprotective, cell adhesion and mitogenic agent (Manson et al., 1992; Martins et al., 2001; Zanata et al., 2002; Chiarini et al., 2002). However, recent studies have demonstrated the capacity of PrP^C to bind molecules involved in signal transduction such as the neural cell adhesion molecule (N-CAM) and laminin. Binding of PrP^C to these molecules results in neurite outgrowth and neuronal proliferation and migration (Santuccione et al., 2005; Graner et al., 2000). A recent report indicated that PrP^C-null mice exhibited an impaired capacity of self-renewal of hematopoietic stem cell populations after serial transplantation in the bone marrow (Zhang et al., 2005). Furthermore, PrP^C was positively associated with proliferation of neural cells *in vivo* and differentiation of multipotent neural precursors *in vitro* (Steele et al., 2005). Since PrP^C is highly expressed in the nervous tissue, PrP^C mediation or activation of cell signaling involved in proliferation or differentiation suggests a role for PrP^C in the development of the nervous system; however, further evidence is required to elucidate this hypothesis.

3

The complex presentation of TSEs and the novel properties of the PrP[Sc] have opened many questions yet to be answered. During the last years, research in prion biology has mainly focused on determination of the pathogenesis of TSEs and the development of diagnostic and therapeutic methods. However, further research in prion biology will continue to be the foundation for understanding the complex nature of TSEs and how these diseases can be controlled.

PRION BIOLOGY

PrP[C] structure. The structure of PrP[C] is highly conserved among species and throughout evolution, suggesting an important biological role (Riek et al., 1996; Gossert et al, 2005). Before post-translational modification, PrP[C] is composed of a sequence of 253 amino acids with a slight variation between species depending on the number of octapeptide repeats (Prusiner and Scott, 1997). The octapeptide repeat region is an eight-amino acid repetitive motif composed of residues P(H/Q)GGG(-/G)WGQ and located in the N-terminal region of the protein (Moore et al., 2006). During protein maturation, PrP[C] is exposed to several modifications in the rough endoplasmic reticulum (ER) including replacement of the peptide signal located between amino acids 232-253 with a glycophosphatidylinositol (GPI) anchor. Additionally, two asparagines at amino acids 181-197 are glycosylated and one disulfide bridge is added between two cysteine residues 179-214 (Prusiner, 1998; Harris, 2003). The mature protein is divided in two distinct regions: a flexible and essentially unstructured N-terminal region between amino acids 23-125 and a C-terminal region containing three alpha-helicoidal structures and a short beta-sheet motif between amino acids 126-231 (Abid and Soto, 2006). Asparagine glycosylation will determine variations in the biochemistry of the mature protein resulting in mono-, di- or un-glycosylated forms with molecular weights of ~28, 34 and 25 Kb, respectively (Russelakis-Carneiro et al., 2002; Priola and Vorberg, 2006). PrP[C] is found as a mixture of these forms with variable proportions depending on the tissue and animal species (Russelakis-Carneiro et al., 2002).

The usual cellular location of PrP[C] is attached by the GPI anchor to membrane domains rich in cholesterol and sphingolipids known as lipid raft (Martins et al., 2002, DeMarco et al., 2005). However, part of the pool of PrP[C] can be internalized via clathrin-mediated endocytosis and accumulate inside the Golgi

apparatus. Furthermore, some of the internalized protein is recycled to the cytoplasmatic membrane by kinesin anterograde transport (Harris et al, 1996; Sunyach et al., 2003; Hachiya et al., 2004). It is uncommon for membrane-anchored proteins to be internalized by clathrin-mediated endocytosis since they are devoid of a cytoplasmic domain that usually recruits clathrin-coated pits. However, this process may be facilitated by unknown proteins that interact with PrP^C, enabling endocytosis of the molecule (Harris et al., 1996). Although the specific location for PrP^C conversion has not yet been determined, it is believed that formation of PrP^{Sc} occurs inside the cell and not in the extracellular suspension. PrP^C has been detected inside endosomes and lysosomes which potentially participate as conversion sites (Martins et al., 2002). The low pH maintained inside these organelles may facilitate PrP^C conversion as demonstrated by experiments in which acid pH favored aggregation of recombinant PrP^C into PrP^{Sc}-like structures (Bocharova et al., 2005). Alternatively, the pool of PrP^C that remains attached to the plasma membrane may find a favorable environment for conversion in lipid rafts that promote protein interaction and recruit accessory molecules (Hooper and Taylor, 2006).

Prnp gene structure. The prion gene (Prnp) has homologues in all vertebrates with conserved regions between mammals and birds (Premzl and Gamulin 2007). Prnp is located in chromosome 2 in mouse, 13 in bovine and 20 in human (Sparkes et al, 1986; Ryan and Womack, 1993). The 5' flanking region of bovine Prnp shows an 89% homology with the sheep and only 46-62% homology with the mouse, rat, hamster and human sequences (Inoue et al., 1997). Bovine, sheep, mouse and rat Prnp possess three exons with the protein coding sequence located entirely within the third exon (Fig. 1; Chesebro et al., 1985; Oesch et al., 1985; Inoue et al., 1996). Using chloramphenicol acetyltransferase (CAT) plasmids, the promoter region of the bovine gene was detected in the region between -88 and -30 relative to the transcription start site, similar to the rat promoter region (Inoue et al., 1997). Several regulatory regions including the promoter has been identified in the bovine Prnp with the major region of transcriptional control located upstream of the initiation site. The promoter sequence is rich in G+C features, lacks a TATA box and contains potential binding sites for Sp-1 transcriptional factors (Inoue et al., 1997). Several variables have been reported to influence Prnp expression under *in vitro* conditions including nerve growth factor (NGF), rate of prion infection and epigenetic changes (Graner et al., 2000; Bueler et al., 1993; Martins et al., 2002). However, *in vivo* factors such as the physiological status of the host may influence Prnp expression as well. A recent study reported that Prnp gene expression may be affected by heat shock proteins under stress conditions (Haigh et al., 2007).

Polymorphic variations in the coding sequence of the ovine Prnp gene have been reported to control the susceptibility to scrapie. The major mutations associated with susceptibility or resistance are located at codons 136 (A or V), 154 (R or H) and 171 (R, Q or H) (Clouscard et al., 1995; Hunter et al., 1996). Animals with PrP genotypes V136 R154Q171/VRQ, ARQ/VRQ and ARQ/ARQ are the most susceptible to scrapie, whereas homozygous or heterozygous AHQ and heterozygous ARR animals show only marginal susceptibility. ARR/ARR sheep are considered to be fully resistant (Hunter et al., 1996).

Prion Hypothesis. The prion hypothesis or protein-only hypothesis postulates that the agent responsible for prion propagation is originated by autocatalytic conversion of PrP^C into the pathogenic isoform (Griffith, 1967). Conversion into PrP^{Sc} involves a drastic alteration in the protein configuration as well as in the biochemical properties. Crystallography studies indicate that in normal state 47% of the PrP^C structure is composed of α-helix and only 3% β-sheet secondary configuration. In the conversion process, the β-sheet configuration is increased to 43-45 % and the α-helix structure is reduced to 17-30% (Pan et al., 1993; DeMarco et al., 2005, Fig.2). Therefore, the newly formed PrP^{Sc} structure is highly planar and stable showing strong resistance to temperature, pH, disinfectants and enzymatic degradation (Taylor, 2000).

Additional supporting evidence of the prion hypothesis has been originated from studies that reported resistance to prion infection in mice lacking the Prnp gene (Bueler et al., 1993). These knockout models not only evidenced the requirement of a host-encoded PrP^C protein for the infection process but also allowed a better understanding of the pathogenesis of TSEs. However, the most compelling evidence to probe this theory is yet to be reported. Some researchers claimed that a confirmatory experiment will consist in the *in vitro* conversion of PrP^C molecules into a pathogenic isoform with the capacity to induce TSE infection (Chesebro, 1998). Mutations induced to recombinant PrP^C have resulted in destabilization of the protein configuration and formation of a PrP^{Sc}-like molecule; however, this mutated agent was unable to induce prion disease (Chiesa et al, 1998; Bocharova et al., 2005). It is possible that additional factors including a transitional form of PrP and host-derived proteins or non-protein compounds (chaperones, glycosaminoglycans or short nucleic acids) are required to sustain *in vitro* generation of PrP^{Sc} (Castilla et al., 2005; Aguzzi et al., 2007). Hamster PrP^C was only converted to PrP^{Sc} when cell lysate was added to the reaction (Deleault et al., 2005). Moreover, mice co-expressing both human and mice PrP were resistant to prion replication as consequence of the interaction of mice PrP^C with an additional factor (termed protein X) that inhibited human PrP^C conversion (Telling et al., 1995). Recent

studies reported the *in vitro* generation of PrP^{Sc} molecules using a protein misfolding cyclic amplification technique (PMCA) that allows the repetitive amplification of the misfolding event (Castilla et al., 2005). Although, the newly formed PrP^{Sc} generated by this technique was able to infect wild-type Syrian hamsters, the use of crude brain homogenates to amplificate these molecules may have also resulted in the addition of different components responsible for the infection.

Two distinct models have been proposed to explain the autocatalytic conversion of PrP^{C}, a process not mediated by nucleic acids that challenge the central dogma of molecular biology. The template-assisted model postulates a thermodynamically stable conversion between both PrP isoforms (Fig. 3). PrP^{C} conversion is induced by PrP^{Sc} and is mediated by an intermediate and heterodimeric unit before the formation of a homodimeric PrP^{Sc}. The process is catalyzed by a yet unidentified protein X that has chaperone-like properties and facilitates aggregation of both isoforms (Cohen and Prusiner, 1998). Protein X promotes PrP^{C} conversion by binding a discontinuous epitope in the globular C terminal region of the protein (Kaneko et al., 1997). Newly formed PrP^{Sc} can eventually agglutinate and precipitate, forming amyloid precursors detected in some TSEs (Prusiner, 1990; Cohen et al., 1999). A second model termed nucleation-polymerization, proposes a similar thermodynamic equilibrium between both isoforms (Fig. 3). However, after PrP^{C} conversion, the model describes a highly unstable and transient PrP^{Sc} molecule that would be stabilized only by forming ordered aggregates. The stabilized oligomers act as nuclei to recruit monomeric PrP^{Sc} in a process that displaces the thermodynamic equilibrium and accelerates PrP^{Sc} formation (Caughey, 2001; Caughey and Lansburry, 2003).

Despite a bulk of evidence in support of the prion hypothesis, alternative models suggesting the participation of viral particles, virinos and small RNAs have also been proposed. Co-sedimentation of retroviral RNA with PrP^{Sc}, and purification of short RNA fragments from infectious fractions suggest the participation of nucleic acids as part of the infectious particle (Akowitz et al., 1990, 1994). The virino model describes the TSE agent as a proteinaceous structure containing nucleic acids with a virus-like conformation (Chesebro, 1998). The finding that prions have a variety of strains that correlates with a species-specific symptomology and histopathology in TSEs has also been used as evidence to support the virino model (Chesebro, 1998). However, the strain phenomenon can be explained by the variation in PrP^{Sc} protein secondary structure and not necessarily by the existence of viral strains containing nucleic acids (Prusiner, 1998). Furthermore, several biochemical properties displayed by scrapie agents indicate the absence of nucleic acids. The molecular weight (< 50 kDa), diameter (4 to 6 nm) and width (1 nm) of

the scrapie agent predicted a reduced core volume (14.1 m3) with insufficient capacity to store enough nucleic acids to encode a viral protein (Prusiner, 1982). Additionally, the prion agent has shown high resistance to UV radiation (42,000 J/m2) and nuclease digestion.

PrP^C Function. Despite intense investigation during recent years, the function of PrP^C remains enigmatic. Some studies have suggested a cellular protective role of PrP^C against oxidative stress. Experiments have showed that neurons obtained from Prnp knockout mice and cultured *in vitro* display higher susceptibility to oxidative agents such as hydrogen peroxide, xanthine oxidase and copper ions compared to wild-type neurons (Brown et al., 2002). Moreover, brain tissue collected from Prnp knockout mice exhibited biochemical changes including increased levels of protein carbonyls and lipid peroxidation products, which are indicative of oxidative stress (Wong et al., 2001). An extensive body of evidence has accumulated suggesting the binding of Cu+2 ions to the PrP^C octapeptide repeat region. Copper (Cu+2) is an essential element that participates as an enzymatic cofactor in the biochemical pathways of all aerobic organisms. However, Cu +2 can also catalyze the formation of reactive oxygen species such as the hydroxyl radical (Martins et al., 2001). The binding of Cu +2 to PrP^C may limit the capacity to catalyze the formation of such toxic oxidative radicals (Martin et al., 2001; Vassallo and Herms, 2003). Some researchers have questioned this antioxidant property due to the super-physiological concentrations of Cu +2 required to activate this process (Westergard et al., 2007). Alternatively, PrP^C may modulate the activity of the Cu/Zn superoxide dismutase (Cu/Zn SOD) enzyme that showed cellular protective function against oxidative stress (Wechslberger et al., 2002; Brown et al., 2001). Analyses in brain tissue obtained from Prnp knockout mice have shown only 10-50% of the normal Cu +2 loading capacity and Cu/Zn SOD enzymatic activity. In contrast, the enzymatic activity and copper loading of Cu/Zn SOD was increased in mice over-expressing PrP^C (Brown et al., 1997).

Several lines of evidence have proposed a cytoprotective role of PrP^C against internal or environmental stresses that initiate apoptosis. This anti-apoptotic potential is primarily based on the capacity of PrP^C to inhibit the action of the apoptotic protein Bax (Bounhar et al., 2001). PrP^C-induced blocking of Bax may be direct, for example by inhibiting its mitochondrial translocation, conformational change, or oligomerization. Alternatively, PrP^C may act upstream of Bax, affecting the activity of BH3, Bcl-2 or Bcl-X$_L$, or downstream, suppressing the effects of Bax in the release of cytochrome c or activation of Apaf-1 and caspases (Roucou et al., 2005; Westergard et al, 2007). PrP^C could also affect the calcium Bax-mediated secretory pathway in the ER. Other studies have reported a close similarity between the

8

homologous domain of the anti-apoptotic protein Bcl-2 and the PrP^C octapeptide region. This analogy in the protein structure may allow PrP^C to mimic Bcl-2 function and induce cell survival (Roucou et al., 2005; Westergard et al., 2007).

In addition to the cytoprotective role, PrP^C has been also implicated as a cell proliferation and differentiation factor. Recently it was reported that PrP^C-null mice exhibited an impaired capacity of self-renewal of hematopoietic stem cell populations after serial transplantation in the bone marrow (Zhang et al., 2005). The potential mitogenic capacity has also been supported by studies showing a decrease in T lymphocyte proliferation in mice devoid of PrP^C (Bainbridge et al., 2005). The role of PrP^C in differentiation was suggested by high levels of expression in cells that ceased proliferation and became differentiated into neurons during early stages of mice embryogenesis (Tremblay et al., 2007). In a recent report, PrP^C displayed a positive effect in the proliferation of neural precursor cells and showed a positive correlation with neuronal differentiation (Steele et al., 2006). In this study, mice over-expressing PrP^C exhibited an increased multipotent neural precursor proliferation in neurogenic regions of the brain. In contrast, ablation of PrP^C resulted in lower neural precursor differentiation compared to wild-type controls.

The capacity of PrP^C to bind to several different molecules has opened the idea that this protein may exert its function in association with a ligand. The location of PrP^C in the extracytoplasmic face of the lipid bilayer restricts the interaction to transmembrane and secreted proteins. Transmembrane variants of PrP^C could potentially interact with cytoplasmic partners; however, these forms are normally present in low amounts in the absence of predisposing mutations in the PrP^C molecule (Stewart et al., 2001). The membrane association and the interaction with ligands suggest the hypothesis that PrP^C may activate transmembrane signaling processes associated to neuronal survival, neurite outgrowth, and neurotoxicity. The stress inducible protein STI-1 has been implicated as a co-chaperone molecule that form part of the heat shock protein (HSP) macromolecular complexes Hsp70 and Hsp 90 (Zanata et al., 2002). The interaction between PrP^C and STI-1 showed high affinity and specificity resulting in neuroprotective functions through the mediators of the cAMP dependent protein kinase (AMPc/PKA) pathway (Zanata et al., 2002; Chiarini et al., 2002). Additionally, interaction with STI-1 induced neuritogenesis through the MAPK pathway as a parallel effect to neuroprotection (Lopes et al., 2005). Neuronal growth has also been observed during PrP^C interaction with the neuron cell adhesion protein N-CAM after its recruitment from lipid rafts and the activation of Fyn kinase (Santuccione et al., 2005). Treatment of cultured neurons

with recombinant PrP^C enhances neurite outgrowth and neuronal survival, concomitant with activation of several kinases, including fyn, PKC, PKA, PI-3 kinase/Akt and ERK (Kanaani et al, 2005; Santuccione et al., 2005).

Laminin is an important glycoprotein of the basal membrane and plays an important role in neuronal proliferation, growth and migration (Westergard et al., 2007). Studies have showed that PrP^C binding to the receptor of laminin is specific and saturable and results in dendritic extension, neuronal migration, axonomic regeneration and suppression of cell death induced by kainic acid injection (Graner et al., 2000, Martin et al., 2001). PrP^C can also interact with the cytoplasmic protein laminin receptor precursor (LRP), which may serve as an endocytic receptor for cellular uptake of both PrP^C and PrP^{Sc} (Gauczynski et al., 2006).

Although, PrP^C has been reported as a cellular anti-apoptotic factor, some experiments have suggested its involvement as neurotoxin effects. Synthetic peptide PrP 106-126 has been used to mimic the effect of PrP^{Sc} on cultured cells (Selvaggini et al., 1993). Incubation with this peptide showed toxic effects on cultured neurons and neuronal cell lines, but only in those that express PrP^C (Forloni et al., 1993; Brown et al., 1994a). These studies suggest that PrP^C may mediate PrP^{Sc} pathogenic action through a signaling pathway.

PrP^C role in TSE pathogenesis. The pathogenesis of TSEs including the mechanism of neuronal degeneration has not been completely elucidated. It is now becoming clear, however, that PrP^{Sc} kills neurons by virtue of its ability to perturb the normal and physiological activities of PrP^C (Westergard et al., 2007). The presence of PrP^{Sc} alone in neuronal cells may result in toxic effects by several mechanisms including blocking axonal transport, interfering with synaptic function, or triggering apoptotic pathways (Westergard et al., 2007). Alternatively, the potential association between PrP^{Sc} and PrP^C during the pathogenic process may result in the loss of PrP^C anti-apoptotic activity, resulting in neuronal death. Evidence that argues against this theory is based on the small phenotypic effect and lack of any features of TSEs observed after ablation of PrP^C either prenatally or postnatally (Bueler et al., 1992; Mallucci et al., 2002). However, it is possible that neurodegeneration may be consequence of both loss and gain in function, by loss of the cytoprotective activity of PrP^C that may become essential in the disease state due to cellular or organism stress.

Another hypothesis for the TSE-pathogenic effect postulates the alteration or subversion of the normal PrP^C neuroprotective function. PrP^C may act as a membrane-anchored signal transduction that transmits the PrP^{Sc} toxic effect (Chesebro et al., 2005). Neurons obtained from PrP^C knockout mice and cultured in vitro were resistant to apoptosis induced by exposure to the synthetic peptide PrP 106-126 (Brown et al., 1994a). This phenomenon may be the consequence of a PrP^{Sc}-induced aggregation of cell surface PrP^C that generate a neurotoxic rather than a neuroprotective signal. Cross-linking of PrP^C using anti-PrP antibodies resulted in apoptosis of neurons in vivo (Solforosi et al., 2004). Alternatively, amino acid sequences (PrPΔ 105-125) in the PrP^C structure have been reported to have receptor activity with cytoprotective functions. These receptor sequences may be blocked by PrP^{Sc} resulting in the delivery of a neurotoxic signal (Li et al., 2007).

BOVINE SPONGIFORM ENCEPHALOPATHY

Epidemiology. Bovine spongiform encephalopathy (BSE) was reported for the first time in the UK in 1986 (Wells et al., 1987). The disease achieved epidemic proportions during the 1990s with more than 182,000 cases worldwide recorded between November of that year and July of 2008. BSE has been detected in 24 countries worldwide showing a decreasing trend in the number of cases since 2003 (2167), 2004 (879), 2005 (561), 2006 (201), 2007 (169) (OIE, 2008).

The origin of BSE has not been clarified but several theories have been formulated. One of these theories postulates the inter-species transmission from scrapie-infected sheep to cattle. Cows became infected after consumption of protein concentrate made from carcasses of sheep contaminated with scrapie. Scrapie has affected sheep for 200 years, is endemic in the UK and is present in a number of countries worldwide (Schwartz, 2003). Although contamination of feed with infected ovine carcasses is possible; experimental transmission of scrapie agent to the bovine has proved difficult, making this hypothesis improbable (Cutlip et al., 1994). A second theory involves the spontaneous destabilization and conversion of PrP^C into PrP^{Sc}. Spontaneous or atypical BSE cases have been reported recently, and animals affected by this disease may have served as a source of protein supplements for cattle feed thus spreading the disease in

this manner (Capiobianco et al., 2007). However, one of the most controversial theories to explain the contamination of animal concentrate is the human origin of BSE. Funeral rituals in areas of India involve the cremation of cadavers and the disposal of human remains to rivers. Some of these remains may have been collected by "bonepickers" and used to elaborate bone meal that eventually might have been contaminated with human TSE. By this process, contaminated bone and meat meal exported from the India to Europe and used for animal consumption may have served as a source of BSE transmission (Colchester and Colchester, 2005).

Causal agent. Detection of PrP^{Sc} is highly correlated with the pathology and diagnosis of BSE. However, the sole presence of PrP^{Sc} as the pathogenic agent of TSEs has been debated. Mice infected with scrapie agent developed lesions in areas of the brain that showed low levels of PrP^{Sc} (Parchi and Gambetti, 1995). Moreover, no brain damage was reported in transgenic mice over-expressing PrP^{Sc} (Chiesa and Harris, 2001). These reports suggest that cellular damage is a consequence not exclusively of PrP^{Sc} but also require the participation of additional cofactors including a transitional form of PrP and host-derived proteins or non-protein compounds (glycosaminoglycans or short nucleic acids; Aguzzi et al., 2007). In this scenario, PrP^{C} may play an important role as a mediator in PrP^{Sc} pathogenesis. Mice infected with PrP^{Sc} in which Prnp gene was knocked out from the beginning or during the infectious process showed that PrP^{C} expression is required for cellular damage (Brandner et al., 1996; Mallucci et al., 2003).

Pathogenesis. There are several origins of prion disease pathogenesis that remain to be understood. It is believed that the TSE agent is passed under natural conditions from one animal to the other through oral ingestion. Indeed, the transmission of the PrP^{Sc} agent by the oral pathway has great relevance in some TSEs (e.g. variant Creutzfeldt-Jakob disease, Kuru and BSE). This is not the case in spontaneous forms of this disease in which genetic predisposition seems to be the causative factor (e.g. spontaneous Creutzfeldt-Jakob). Although oral ingestion of the agent is the most commonly known form of contamination, other ways of infection cannot be overlooked, such as injection of contaminated products, skin injuries or iatrogenic ways (Mabbot and MacPherson, 2006). The transport of PrP^{Sc} through the intestinal mucosa is mediated by microfold cells (M cells) located within the epithelium villus and follicle-associated epithelium (FAE) of the Peyer's patches, through the process of transcytosis (Heppner et al., 2001). Under physiological conditions, M cells sample contents of the intestinal lumen and present these antigens to the host immune system for immunomodelation. Some pathogenic microorganisms and potentially PrP^{Sc} can exploit M cells transcytosis to gain entry into mucosal tissues (Neutra et al., 1996).

The transport of TSE agents across the intestinal epithelium; however, might not be entirely mediated by M-cell-transcytosis. PrP^{Sc}-proteon complexes originated from CJD brain homogenate can be endocytosed by intestinal epithelial cells (Caco-2 cells) and transcytosed in vesicular structures by a ferritin-dependent mechanism (Mishra et al., 2004).

After transport through the intestinal mucosa, PrP^{Sc} particles are captured by several types of cells including macrophages, lymphocytes and dendritic cells (DCs) and presented to follicular dendritic cells (FDCs) in the lamina propia. The precise involvement of macrophages in TSE pathogenesis is uncertain but these cells may mediate the transport and also the impairment of PrP^{Sc} accumulation. A recent *in vitro* study showed that macrophage depletion resulted in an earlier increase in PrP^{Sc} accumulation in the lymphoid tissue (Maignien et al, 2005). Lymphocytes are also situated intraepithelial, but are unlikely to be involved in transporting PrP^{Sc} as they do not acquire measurable levels of this agent following intra-intestinal exposure (Huang et al., 2002). DCs are a distinct lineage from stromal derived FDCs that sample antigens in the periphery and deliver them to lymphoid tissues to initiate an immune response (Shortman and Liu, 2002). The location of DCs beneath intraepithelial M cells and their capacity to acquire intestinal antigens by inserting their dendrites between tight junctions (independently from M cells) make these cells good candidates to transport PrP^{Sc} to lymphoid tissues (Beekes and McBride, 2000).

Analysis of the distribution of the PrP^{Sc} within the nervous system of orally inoculated rodents indicates that the agent subsequently spreads from the gut-associated lymphoid tissue (GALT) to the CNS through the enteric nervous system in a process known as neuroinvasion (Beekes and McBride, 2000). The enteric nervous system is an important component of the autonomic nervous system and regulates intestinal motility and secretions through stimuli from sympathetic and parasympathetic nerves. PrP^{Sc} reaches the CNS by spreading in a retrograde direction along efferent fibers of both sympathetic and parasympathetic nerves until they contact the spinal cord. It is not understood how PrP^{Sc} initially spread from the FDCs to the peripheral nervous system. This process may be mediated by mobile intermediate cells or exosomes derived from FDCs, DCs or macrophages that transport PrP^{Sc} particles from FDCs to the peripheral nervous system (Mabbot and MacPherson, 2006). Potential neuroinvasion through the blood-brain barrier has also been suggested; however, the localization of PrP^{Sc} deposits and blood vessels in brains of patients with vCJD does not reflect a haematogenous pattern (Armstrong et al., 2003; Mabbot y MacPherson 2006).

Histopathological changes. In general, histopathological changes observed in TSEs are associated with spongiform degeneration, vacuolization, astrogliosis and PrP^{Sc} deposition (Budka, 1995, MacDonald et al., 1996). However, astrogliosis and neuronal loss are not evident in BSE compared to other TSEs. The presence of amyloid plaques are rare in classic BSE and are mostly found in the thalamus. In contrast, atypical BSE or Bovine Amyloidotic Spongiform Encephalopathy (BASE) has been characterized by the presence of large plaques mainly in the white matter. The molecular signature of BASE also differs from BSE and resembles CJD (Casalone et al., 2004). Several theories have been proposed to explain BASE presentation including spontaneous occurrence of TSE in animals as in sporadic CJD. Classic BSE is also characterized by spongiosis and vacuolization of the neuropil and neuronal bodies through simple or multiple vacuoles in the neuronal perikarya (Wells et al., 1989). Neural tissues most consistently and severely affected are the solitary tract nucleus, the spinal tract nucleus of the trigeminal nerve, and the central gray matter of the midbrain (Wells et al., 1989). Neuropil vacuolization of the target nuclei is considered to be pathognomic in BSE. Intraneuronal vacuolation is also observed in BSE, but this feature alone in the absence of neuropil vacuolation is not confirmatory. Vacuolated neurons particularly in certain locations such as the red nucleus may be an incidental finding in cattle (Gavier-Widen et al., 2001). Immunohistochemical analysis consistently reveals PrP^{Sc} accumulation in the brain, with distribution similar to but often more widespread than neuropil vacuolation. Patterns of PrP^{Sc} deposition in the brain include intraneuronal, perineuronal, linear, fine punctuate and coarse particulate (Wells and Wilesmith, 1995). PrP^{Sc} cannot readily be detected in tissues outside bovine CNS; however, limited involvement of the Peyer's patches has been documented in experimentally induced and naturally acquired cases of BSE (Terry et al., 2003).

Diagnosis. All diagnostic methods currently available require post-mortem confirmation. Despite characteristic clinical signs, diagnosis of BSE cannot rely solely on the clinical course and requires histopathological analysis. Initial histopathological diagnosis is based on vacuolar changes in the brain, observation of florid plaques, astrogliosis and neuronal loss. However, presentation of cases with no evident or ambiguous histopathological changes requires confirmation through more specific and sensitive methods such as immunohistochemistry, western blot and/or ELISA (Gavier-Widen et al., 2005, OIE, 2004). Given the pivotal role played by PrP^{Sc} in TSE pathogenesis, diagnostic methods rely on PrP^{Sc} detection by specific antibodies and partial proteinase K digestion that allows differentiation between both PrP isoforms. In recent years, some antibodies have claimed to differentiate between PrP^{C} and PrP^{Sc};

however, none of these molecules have proved suitable for direct identification of PrP^{Sc} (Korth et al., 1997; Curin et al., 2004; Zou et al., 2004).

Consistent early accumulation of PrP^{Sc} and vacuolar lesions in the medulla oblongata at the level of the obex (brainstem) make this area of the brain an optimal site for the post-mortem diagnosis of BSE. An appropriate sample for BSE diagnosis should include the solitary and trigeminal tract nuclei (Jeffrey and Gonzales, 2004). Brainstem sample may be conveniently obtained by introducing a commercially available, long, spoon-shaped metal or disposable instrument with cutting edges through the foramen magnum to facilitate sampling of the brainstem. Alternatively, the sample could be obtained by dismantling the calvarium (e.g. when retrieving the whole brain for rabies diagnosis). The brainstem sample should be promptly refrigerated (at 4°C not frozen) or fixed in 10% formaldehyde until shipment to the diagnostic laboratory to avoid post-mortem decomposition (Gavier-Widen 2005, USDA, 2006).

Several diagnostic methods based on immunological techniques have been validated and officially accepted for BSE. Currently, the BioRad diagnostic immunoassay is used as a rapid test for BSE detection. Advantages of this method include easy manipulation, fast results (24 h), high sensitivity, and detection of PrPSc infection during preclinical stages (Soto, 2006). This immunoassay is based on the capture of PrP^{Sc} present in the sample by antibodies attached to a microtitulation plate. Incubation of captured PrP^{Sc} by anti-PrP antibodies allows secondary antibody detection and visualization with a colorimetric reaction. However, high presentation of false positive results by this method recommends the use of confirmatory techniques (USDA, 2005). High specificity, visualization of the spongiform lesions and PrP^{Sc}-specific immunostaining make the immunohistochemistry a primary choice for confirmatory diagnosis of BSE. This method requires formalin-fixation and paraffin-embedding of the samples. Tissue is sectioned and mounted in glass slides. Mounted tissue sections are exposed to proteinase K digestion and epitope unmasking through immersion in citric buffer. PrPSc is detected by incubation with anti-PrP antibodies followed by secondary antibodies associated to horseperoxidase staining or fluorescence dyes (OIE, 2004). Samples with moderate levels of decomposition may not be suitable for the immunohistochemistry method but may be used for western blot analysis. This method has similar specificity compared to immunohistochemistry but does not allow histological analysis. Currently, this technique can be performed in a short period of time with high sensitivity. Tissue sample lysates are treated with proteinase K for PrP^{C} digestion. Total protein contained in samples are separated by electrophoresis in 12% SDS polyacrylamide gels and blotted into nitrocellulose or polyvinylidene

fluoride (PVDF) membranes. PrP^{Sc} is specifically detected by incubation with anti-PrP antibodies followed by secondary antibodies.

The requirement of a pre-mortem diagnostic method is desirable considering the inability to apply conventional methods for nucleic acids or antiserum detection such as PCR or ELISA. During the last years, substantial efforts have been applied in the development of PrP^{Sc}-specific antibodies for the potential diagnostic of infectivity in fluids and tissues. Despite the significant differences in secondary structure between both PrP isoforms, the development of such antibodies is still incomplete (Demart et al., 1999, Groschup et al., 1997, Kascsak et al., 1997, Curin et al., 2004). PrP^{Sc} has been detected in the blood of infected animals, which represents a potential strategy for early diagnosis of TSEs (Castilla et al., 2005). However, levels of PrP^{Sc} in blood are very low making even highly sensitive techniques such as immunocapillary electrophoresis unable to detect the agent (Schmerr and Jenny., 1998). One important step in the development of such a diagnostic tool was the recently reported development of a protein misfolding cyclic amplification technique (PMCA). This method was able to simulate PrP^{Sc} replication in a test tube and increase the detection threshold of this protein by 10 million times (Castilla et al., 2005). This new technology enables an efficient, specific and rapid detection of prions offering great promise for developing a noninvasive early diagnosis of TSEs.

Conclusions. The complex nature of the prion biology has intrigued the scientific community for more than 70 years and yet there are many questions to be answered. The establishment of the controversial prion hypothesis opened a new perspective in protein biology that involved the participation of these molecules in diseases as pathogenic and infectious agents. Not only TSEs, but other neurodegenerative diseases such as Alzheimer's have showed to be the consequence of the misfolding and deposition of host-encoded proteins with severe neuropathology. Currently, there are no ways to cure, treat or immunize against these diseases, and the consequences for public health and economic costs have proven to be tremendous. However, important advances during the last years in the evaluation of prion biology have allowed a better understanding of the pathogenesis of this disease and have opened new opportunities for treatment.

One of the most intriguing aspects in prion biology is the still enigmatic physiological function of the PrP^C. This mysterious protein has been implicated in several biological processes including cellular

protection against oxidative stress and apoptosis, cell-to-cell adhesion, cellular proliferation and differentiation. Recently, important evidence has been reported supporting the idea that PrP^C is involved in signaling pathways associated with cellular proliferation and differentiation. In the present work, we first describe the analyses performed to characterize the expression of PrP^C in several somatic and reproductive tissues. These analyses suggest the participation of PrP^C in various physiological processes involving cellular differentiation and tissue development. Therefore, in the final two chapters we describe the efforts to elucidate the potential participation of PrP^C in cellular differentiation by the utilization of developmental models including embryos and embryonic stem cells.

Bovine PrP^C gene expression

Figure 1. Structure of the Prnp gene and mRNA. The Prnp gene size is aproximate 21 kb. After transcription and splicing, the mRNA molecule is formed by the exons 1, 2 and 3. Exon 3 carries the coding sequence that encodes the PrP^C protein after translation.

PrP isoforms structure

PrP^C

47% α-helix

3% β-sheet

PrP^{Sc}

17-30% α-helix

43-45% β-sheet

Figure 2. Structure of PrP^C and PrP^{Sc} isoforms. PrP^C and PrP^{Sc} have important differences in secondary protein configuration. Structure of PrP^C is conformed by a high α-helicoidal (47%) and low β-sheet configuration (3%). In contrast, PrP^{Sc} is characterized by high β-sheet (43-45%) and low α-helicoidal (17-30%) proportion.

Figure 3. Models for conversion between PrP^C and PrP^{Sc}. The template assisted model includes the participation of a conversion factor that mediates PrP conversion. The nucleation-polymerization model describes a PrP^{Sc} heterodimer intermediate complex that induces aggregation and conversion. Both models propose a thermodynamic equilibrium for PrP^C-PrP^{Sc} conversion (Soto, 2006).

LITERATURE CITED

Abid K, Soto C. 2006. The intriguing prion disorders. Cell Mol Life Sci 63, 2342-2351.

Aguzzi A, Heikenwalder M, Polymenidou M. 2007. Insights into prion strains and neurotoxicity. Nat Rev Mol Cell Biol 8, 552-561.

Akowitz A, Sklaviadis T, Manuelidis EE, Manuelidis L. 1990. Nuclease-resistant polyadenylated RNAs of significant size are detected by PCR in highly purified Creutzfeldt-Jakob disease preparations. Microb Pathog 9, 33-45.

Akowitz A, Sklaviadis T, Manuelidis L. 1994. Endogenous viral complexes with long RNA cosediment with the agent of Creutzfeldt-Jakob disease. Nucleic Acids Res. 22, 1101-1107.

Alper T, Haig DA, Clarke MC. 1966. The exceptionally small size of the scrapie agent. Biochem Res Commun 22, 278-284.

Armstrong RA, Cairns NJ, Ironside JW, Lantos PL. 2003. Does the neuropathology of human patients with variant Creutzfeldt-Jakob disease reflect haematogenous spread of the disease? Neurosci Lett 348, 37-40.

Bainbridge J, Walker KB. 2005 The normal cellular form of prion protein modulates T cell responses. Immunol Lett 15, 147-150.

Beekes M, McBride PA. 2000. Early accumulation of pathological PrP in the enteric nervous system and gut-associated lymphoid tissue of hamsters orally infected with scrapie. Neurosci Lett 278, 181-184.

Berg LJ. 1994. Insights into the role of the immune system in prion diseases. Proc Natl Acad Sci USA 18, 91, 429-432.

Bocharova OV, Breyedo L, Parfenov AS, Salnikov VV and Baskakov IV. 2005. In vitro conversion of full-length mammalian prion protein produces amyloid form with physical properties of PrP (Sc). J Mol Biol 346, 645-659.

Bounhar Y, Zhang Y, Goodyer CG, LeBlanc A. 2001. Prion protein protects human neurons against Bax-mediated apoptosis. J Biol Chem 19, 39145-39149.

Brandner S, Isenmann S, Raeber A, Fischer M, Sailer A, Kobayashi Y, Marino S, Weissmann C, Aguzzi A. 1996. Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature 379, 339-343.

Brown DR, Herms J, Kretzschmar HA. 1994. Mouse cortical cells lacking cellular PrP survive in culture with a neurotoxic PrP fragment. NeuroReport 5, 2057-2060.

Brown DR, Schulzschaeffer WJ, Schmidt B, Kretzschmar HA. 1997. Prion protein-deficient cells show altered response to oxidative stress due to decreased SOD-1 activity. Exp Neurol 146, 104-112.

Brown DR. 2001. Prion and prejudice: normal protein and the synapse. Trends Neurosci 24, 85-90.

Brown DR, Nicholas RS, Canevari L. 2002. Lack of prion protein expression results in a neuronal phenotype sensitive to stress. J Neurosci Res 67, 211-224.

Budka H, Aguzzi A, Brown P, Brucher JM, Bugiani O, Gullotta F, Haltia M, Hauw JJ, Ironside JW, Jellinger K. 1995. Neuropathological diagnostic criteria for Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases). Brain Pathol 5, 459-466.

Bueler H, Fischer M, Lang Y, Fluethmann H, Lipp H-P, DeArmond SJ, Prusiner SB, Aguet M, Wissmann C. 1992. Normal development and behavior of mice lacking the neuronal cell-surface PrP protein. Nature 356, 577-582.

Bueler H, Aguzzi A, Sailer A, Greiner RA, Autenried P, Aguet M and Weissman C. 1993. Mice devoid of PrP are resistant to scrapie. Cell 73, 1339-1347.

Casalone C, Zanusso G, Acutis P, Ferrari S, Capucci L, Tagliavini F, Monaco S, Caramelli M. 2004. Identification of a second bovine amyloidotic spongiform encephalopathy: molecular similarities with sporadic Creutzfeldt-Jakob disease. Proc Natl Acad Sci USA 101, 3065-3070.

Capobianco R, Casalone C, Suardi S, Mangieri M, Miccolo C, Limido L, Catania M, Rossi G, Di Fede G, Giaccone G, Bruzzone MG, Minati L, Corona C, Acutis P, Gelmetti D, Lombardi G, Groschup MH, Buschmann A, Zanusso G, Monaco S, Caramelli M, Tagliavini F. 2007. Conversion of the BASE prion strain into the BSE strain: the origin of BSE? PloS Pathog 3, e31.

Castilla J, Saa P, Hetz C, Soto C. 2005. In vitro generation of infectious scrapie prions. Cell 121, 195-206.

Caughey B. 2001. Interactions between prion protein isoforms: the kiss of death? Trends Biochem Sci 26, 235-242.

Caughey B, Lansbury PT. 2003. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 26, 267-298.

Chesebro B, Race R, Wehrly K, Nishio J, Bloom M, Lechner D, Bergstrom S, Robbins K, Mayer L, Keith JM, Garon C, Haase A. 1985. Identification of scrapie prion protein-specific mRNA in scrapie-infected and uninfected brain. 315, 331-333

Chesebro B. 1998. BSE and prions: uncertainties about the agent. Science 279, 42-43.

Chesebro B, Trifilo M, Race R, Meade-White K, Teng C, LaCasse R, Raymond L, Favara C, Baron G, Priola S, Caughey B, Masliah M, Oldstone. 2005. Anchorless prion protein results in infectious amyloid disease without clinical scrapie. Science 308, 1435-1439.

Chiesa R, Harris DA. 2001. Prion diseases: what is the neurotoxic molecule? Neurobiol Dis 8, 743-763.

Chiarini L, Freitas A, Zanata S, Brentani R, Martins V, Linden R. 2002. Cellular prion protein transduces neuroprotective signals. EMBO J 21, 3317-3326.

Chiesa R, Piccardo P, Ghetti B and Harris DA. 1998. Neurological illness in transgenic mice expressing a prion protein with an insertional mutation. Neuron 21, 1339-1351.

Clouscard C, Beaudry P, Elsen JM, Milan D, Dussaucy M, Bounneau C, Schelcher F, Chatelain J, Launay JM, Laplanche JL. 1995. Different allelic effects of the codons 136 and 171 of the protein gene in sheep with natural scrapie. Journal of General Virology, 76, 2097-2101.

Coffey B, Mintert J, Fox S, Schroeder T, Valentin L. 2005. The economic impact of BSE on the US beef industry: product value losses, regulatory costs, and consumer reactions. In: Kansas State University.

Cohen FE, Prusiner SB. 1998. Pathologic conformations of prion proteins. Annu Rev Biochem 67, 793-819.

Cohen FE. 1999. Protein misfolding and prion diseases. J Mol Biol 293, 313-320.

Colchester AC, Colchester NT. 2005. The origin of bovine spongiform encephalopathy: the human prion disease hypothesis. Lancet 366, 856-861.

Collee JG, Bradley R, Liberski PP. 2006. Variant CJD (vCJD) and bovine spongiform encephalopathy (BSE): 10 and 20 years on: part 2. Folia Neuropathol 44, 102-110.

Collinge J. 2001. Prion diseases of humans and animals: their causes and molecular basis. Annu Rev Neurosci 24, 519-550.

Cullie J, Chele PL. 1938. La tremblante du mouton est bien inoculable C. R. Acad Sci (Paris) 206, 78-79.

Curin Serbec V, Bresjanac M, Popovic M, Pretnar Hartman K, Galvani V, Rupreht R, Cernilec M, Vranac T, Hafner I, Jerala R. 2004. Monoclonal antibody against a peptide of human prion protein discriminates between Creutzfeldt-Jacob's disease-affected and normal brain tissue. J Biol Chem 279, 3694-3698.

Cutlip RC, Miller JM, Race RE, Jenny AL, Katz JB, Lehmkuhl HD, DeBey HM, Robinson MM. 1994. Intracerebral transmission of scrapie to cattle. J Infect Dis 169, 814-820

Deleault NR, Geoghegan JC, Nishina K, Kascsak R, Williamson RA, Supattapone S. 2005. Protease-resistant prion protein amplification reconstituted with partially purified substrates and synthetic polyanions. J Biol Chem 280, 26873-26879.

DeMarco ML, Daggett V. 2005. Local environmental effects on the structure of the prion protein. C R Biol 328, 847-862.

Demart S, Fournier JG, Creminon C, Frobert Y, Lamoury F, Marce D, Lasmezas C, Dormont D, Grassi J, Deslys JP. 1999. New insights into abnormal prion protein using monoclonal antibodies. Biochem Biophys Res Commun 265, 652-657.

Forloni G, Angeretti N, Chiesa R, Monzani E, Salmona M, Bugiani O, Tagliavini F. 1993. Neurotoxicity of a prion protein fragment. Nature 362, 543-546.

Gajdusek DC, Gibbs CJ Jr, Alpers M. 1966. Experimental transmission of a kuru-like syndrome to chimpanzees. Nature 209, 794-96.

Gauczynski S, Nikles D, El-Gogo S, Papy-Garcia D, Rey C, Alban S, Barritault D, Lasmezas CI, Weiss S. 2006. The 37-kDa/67-kDa laminin receptor acts as a receptor for infectious prions and is inhibited by polysulfated glycanes. J Infect Dis 194, 702-709.

Gavier-Widen D, Wells GA, Simmons MM, Wilesmith JW, Ryan J. 2001. Histological observations on the brains of symptomless 7-year-old cattle. J Comp Pathol 124, 52-59

Gordon WS. 1946. Advances in Veterinary Research. Vet Rec 58, 516.

Gossert AD, Bonjour S, Lysek DA, Fiorito F, Wuthrich K. 2005. Prion protein NMR structures of elk and of mouse/elk hybrids. Proc Natl Acad Sci USA 102, 646-650.

Graner E, Mercandante AF, Zanata SM, Orestes VF, Cabral ALB, Veiga SS, Juliano MA, Roesler R, Walz R, Minetti A, Izquierdo I, Martins VR, Bretani RR. (2000) Cellular prion protein binds laminin and mediates neuritogenesis. Mol Brain Res 76, 85-92.

Griffith JS. 1967. Self-replication and scrapie. Nature, 215, 1043-1044.

Groschup MH, Harmeyer S, Pfaff E. 1997. Antigenic features of prion proteins of sheep and other mammalian species. J Immunol Methods 207, 89-101.

Hachiya NS, Watanabe K, Yamada M, Sakasegawa Y, Kaneko K. 2004. Anterograde and retrograde intracellular trafficking of fluorescent cellular prion protein. Biochem Biophys Res Comm 315, 802-807.

Hadlow WJ. 1959. Scrapie and kuru. Lancet 2, 289-290.

Haigh CL, Wright JA, Brown DR. 2007. Regulation of prion protein expression by noncoding regions of the Prnp gene. J Mol Biol 368, 915-927.

Harris DA, Gorodinsky A, Lehmann S, Moulder K, Shyng SL. 1996. Cell biology of the prion protein. Curr Top Microbiol Immunol 207, 77-93.

Harris, DA. 2003. Trafficking, turnover and membrane topology of PrP. Br Med Bull. 66, 71-85.

Heppner FL, Christ AD, Klein MA, Prinz M, Fried M, Kraehenbuhl JP, Aguzzi A. 2001. Transepithelial prion transport by M cells. Nature Med 7, 976-977.

Hooper NM, Taylor DR. 2006. The prion protein and lipid rafts (Review). Mol Mem Biol 23, 1, 89-99.

Huang F-P, Farquhar CF, Mabbot NA, Bruce ME, MacPherson GG. 2002. Migrating intestinal dendritic cells transport PrPSc from the gut. J Gen Virol 83, 267-271.

Hunter N, Foster JD, Goldmann W, Stear MJ, Hope J, Bostock C. 1996. Natural scrapie in a closed flock of Cheviot sheep occurs only in specific PrP genotypes. Archives of Virology 141, 809-824.

Inoue S, Tanaka M, Horiuchi M, Ishiguro N, Shinagawa M. 1997. Characterization of the bovine protein gene: The expression requires interaction between the promoter and intron. J Vet Med Sci 59, 175-183.

Jeffrey M, Gonzales L. 2004. Pathology and pathogenesis of bovine spongiform encephalopathy and scrapie. Curr Topics Microbiol Immunol 284, 65-97.

Kanaani J, Prusiner SB, Diacovo J, Baekkeskov S, Legname G. 2005. Recombinant prion protein induces rapid polarization and development of synapses in embryonic rat hippocampal neurons in vitro. J Neurochem 95, 1373-1386.

Kaneko K, Zulianello L, Scott M, Cooper CM, Wallace AC, James TL, Cohen FE, Prusiner SB. 1997. Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation. Proc Natl Acad Sci USA. 94, 10069-10074.

Kascsak RJ, Fersko R, Pulgiano D, Rubenstein R, Carp RI. 1997. Immunodiagnosis of prion disease. Immunol Invest 26, 259-268.

Korth C, Stierli B, Streit P, Moser M, Schaller O, Fischer R, Schulz-Schaeffer W, Kretzchmar H, Raeber A, Braun U, Ehrensperger F, Hornemann S, Glockshuber R, Riek R, Billeter M, Wuthrich K, Oesch B. 1997. Prion (Prpsc)-specific epitope defined by a monoclonal-antibody. Nature 390, 74-77.

Li A, Christensen HM, Stewart LR, Roth KA, Chiesa R, Harris DA. 2007. Neonatal lethality in transgenic mice expressing prion protein with a deletion of residues 105-125, EMBO J 26, 548-558.

Lopes MH, Hajj GN, Muras AG, Mancini GL, Castro RM, Ribeiro KC, Brentain RR, Linden R, Martins VR. 2005. Interaction of cellular prion and stress-inducible protein 1 promotes neuritogenesis and neuroprotection by distinct signaling pathways. J Neurosci 25, 11330-11339.

Mabbott NA, MacPherson GG. 2006. Prions and their lethal journey to the brain. Nat Rev Microbiol 4, 201-211.

Maignien T, Shackweh M, Calvo P, Marce D, Sales N, Fattal E, Deslys JP, Couvreur P, Lasmezas CI. 2005. Role of gut macrophages in mice orally contaminated with scrapie or BSE. Int J Pharm 298, 293-304.

Mallucci GR, Ratte S, Asante EA, Linehan J, Gowland I, Jefferys JG, Collinge J. 2002. Post-natal knockout of prion protein alters hippocampal CA1 properties, but does not result in neurodegeneration. EMBO J 21, 202-210

Mallucci GR, Dickinson A, Linehan J, Klohn PC, Brandner S, Collinge J. 2003. Depleting neuronal PrP in prion infection prevent disease and reverses spongiosis. Science 302, 871-874.

Manson J, West JD, Thomson V, McBride P, Kaufman MH, Hope J. 1992. The prion protein gene: a role in mouse embryogenesis? Development 115, 117-122.

Martins V, Mercadante A, Cabral A, Freitas A, Castro R. 2001. Insights into the physiological function of cellular prion protein. Braz J Med Biol Res 34, 585-595.

Martins VR, Linden R, Prado M, Walz R, Sakamoto AC, Izquierdo I, Brentani RR. 2002. Cellular prion protein: on the road for functions. FEBS Letters 512, 25-28.

McDonald ST, Sutherland K, Ironside JW. 1996. Prion protein genotype and pathological phenotype studies in sporadic Creutzfeldt-Jakob disease. Neuropathol Appl Neurobiol 22, 285-292.

Mishra RS, Basu S, Gu Y, Luo X, Zou WQ, Mishra R, Li R, Chen SG, Gambetti P, Fujioka H, Singh N. 2004. Protease-resistant human prion protein and ferritin are cotransported across Caco-2 epithelial cells: Implications for species barrier in prion uptake from the intestine. J Neurosci 24, 11280-11290.

Moore RA, Herzog C, Errett J, Kocisko DA, Arnold KM, Hayes SF, Priola SA. 2006. Octapeptide repeat insertions increase the rate of protease-resistant prion protein formation. Protein Science 15, 609-619.

Neutra MR, Frey A, Kraehenbuhl JP. 1996. Epithelial M cells: gateways for mucosal infection and immunization. Cell 86, 345-348.

Oesch B, Westaway D, Walchili M, Mckinley MP, Kent SB, Aebersol R, Barry RA, Tempst P, Teplow DB, Hood LE, Prusiner SS and Weissman C. 1985. A cellular gene encodes scrapie PrP 27-30 protein. Cell 40, 735-746.

Office International des Epizooties (OIE). 2004. Bovine spongiform encephalopathy. In: Manual of diagnostic tests and vaccines for terrestrial animals (mammals, birds and bees), 5th ed. Vol I, Paris.

Office International des Epizooties (OIE). 2008. Number of reported cases of bovine spongiform encephalopathy (BSE) in farmed cattle worldwide. http://www.oie.int/eng/info/en_esbmonde.htm

Palmer MS, Dryden AJ, Hughes JT, Collinge J. 1991. Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease. Nature 352, 340-342.

Pan KM, Baldwin M, Nguyen J, Gasset M, Serban A, Groth D, Mehlhorn I, Huang Z, Fletterick RJ, Cohen FE and Prusiner. 1993 Conversion of alpha-helices into β-sheets features in the formation of scrapie prion proteins. Proc Natl Acad Sci USA 90, 10962-10966.

Parchi P, Gambetti P. 1995. Human prion disease. Curr Opin Neurol 8, 286-293.

Premzl M, Gamulin V. 2007. Comparative analysis of prion genes. BMC Genomics 8, 1.

Priola S, Vorberg I. 2006. Molecular aspects of disease pathogenesis in the transmissible spongiform encephalopathies. Mol Biotech, 33, 71-88.

Prusiner SB. 1982. Novel proteinaceous infectious particles cause scrapie. Science 216, 136-144.

Prusiner SB. 1990. Novel structure and genetics of prions causing neurodegeneration in humans and animals. Biologicals 18, 247-262.

Prussiner SB and Scott MR. 1997. Genetics of prions Annu Rev Genet 31, 139-175.

Prusiner SB. 1998 Prions. Proc Natl Acad Sci USA 95, 13363-13383.

Riek R, Hornemann S, Wider G, Billeter M, Glockshuber R, Wuthrich K. 1996. NMR structure of the mouse prion protein domain PrP (121-321). Nature 11, 180-182.

Roucou X, Giannopoulos PN, Zhang Y, Jodoin J, Goodyer CG, LeBlanc A. 2005. Cellular prion protein inhibits proapoptotic Bax conformational change in human neurons and in breast carcinoma MCF-7 cells. Cell Death Differ 12, 783-795.

Russelakis-Carneiro M, Saborio GP, Anderes L, Soto C. 2002. Changes in the glycosylation pattern of prion protein in murine scrapie. Implications for the mechanism of neurodegeneration in prion diseases. J Biol Chem 277, 36872-36877.

Ryan AM, Womack JE. 1993. Somatic cell mapping of the bovine prion protein gene and restriction fragment length polymorphism studies in cattle and sheep. Anim Genet 24, 23-26.

Santuccione A, Sytnyk V, Leshchyns'ka I, Schachner M. 2005. Prion protein recruits its neuronal receptor NCAM to lipid rafts to activate p59fyn and to enhance neurite outgrowth. J Cell Biol 169, 341-354.

Schmerr MJ, Jenny A. 1998. A diagnostic test for scrapie-infected sheep using a capillary electrophoresis immunoassay with fluorescent-labeled peptides. Electrophoresis 19, 409-414.

Schwartz M. 2003. How the cows turned mad. Berkeley: University of California Press.

Selvaggini C, De Gioia L, Cantu L, Ghibaudi E, Diomede L, Passerini F, Forloni G, Bugiani O, Taglivini F, Salmona M. 1993. Molecular characteristics of a protease-resistant, amyloidogenic and neurotoxic peptide homologous to residues 106-126 of the prion protein. Biochem Biophys Res Commun. 194, 1380-1386.

Shortman K, Liu Y-J. 2002. Mouse and human dendritic cell subtypes. Nature Rev Immunol 2, 151-161.

Solforosi L, Criado JR, McGavern DB, Wirz S, Sanchez-Alavez M, Sugama S, DeGiorgio LA, Volpe BT, Wiseman E, Abalos G, Masliah E, Gilden D, Oldstone MB, Conti B, Williamson RA. 2004. Cross-linking cellular prion protein triggers neuronal apoptosis *in vivo*. Science 303, 1514-1516.

Soto C. 2006. Prions. The new biology of proteins. CRC Press. Boca Raton, FL, USA

Sparkes RS, Simon M, Cohn VH, Fournier RE, Lem J, Klisak I, Heinzmann C, Blatt C, Lucero M, Mohandas T, DeArmond SJ, Westaway D, Prusiner SB, Weiner LP. 1986. Assignment of the human and mouse prion protein genes to homologous chromosomes. Proc Natl Acad Sci USA 83, 7358-7362.

Steele AD, Emsley JG, Ozdinler PH, Lindquist S, and Macklis J. 2006. Prion protein (PrPC) positively regulates neural precursor proliferation during developmental and adult mammalian neurogenesis. PNAS, 103, 3416-3421.

Stewart RS, Harris DA. 2001. Most pathogenic mutations do not alter the membrane topology of the prion protein. J Biol Chem 276, 2212-2220.

Sunyach C, Jen A, Deng J, Fitzgerald KT, Frobert Y, Grassi J, McCaffrey MW and Morris R. 2003. The mechanism of internalization of glycosylphosphatidylinositol-anchored prion protein. EMBO J. 22, 3591-3601.

Taylor DM. 2000. Inactivation of transmissible degenerative encephalopathy agents: a review Vet J 159, 10-17.

Telling GC, Scott M, Mastrianni J, Gabizon R, Torchia M, Cohen FE, DeArmond SJ, and Prusiner SG. 1995. Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. Cell 83, 79-90.

Terry LA, Marsh S, Ryder SJ, Hawkins SA, Wells GA, Spenser YI. 2003. Detection of disease-specific PrP in the distal ileum of cattle exposed orally to the agent of bovine spongiform encephalopathy. Vet Rec 152, 387-392.

Tremblay P, Bauzamondo-Bernstein E, Heinrich C, Prusiner SB, DeArmond SJ. 2007. Developmental expression of PrP in the post-implantation embryo. Brain Res 30, 60-67.

United States Department of Agriculture (USDA). 2005. Animal and Plant Health Inspection Service. Factsheet, BSE Confirmatory Tests.

Vassallo N, Herms J. 2003. Cellular prion protein function in copper homeostasis and redox signaling at the synapse. J Neurochem. 86, 538-544.

Wechselberger C, Wurm S, Pfarr W, Hoglinger O. 2002. The physiological functions of prion protein Exp Cell Res 281, 1-8.

Wells GA, Scott AC, Johnson CT, Gunning RF, Hancock M, Jeffrey M, Dawson M, Bradley R. 1987. A novel progressive spongiform encephalopathy in cattle. Vet Rec 121, 419-420.

Wells GAH, Hancock RD, Cooley WA, Richards MS. 1989. Bovine spongiform encephalopathy: diagnostic significance of vacuolar changes in selected nuclei of the medulla oblongata. Vet Rec 125, 521-524.

Wells GAH, Wilesmith JW. 1995. The neuropathology and epidemiology of bovine spongiform encephalopathy. Brain Pathol 5, 91-103.

Westaway D, Zuliani V, Cooper CM, Da Costa M, Neuman S, Jenny AL, Detwiler L, Prusiner SB. 1994. Homozygosity for prion protein alleles encoding glutamine-171 renders sheep susceptible to natural scrapie. Genes Dev 8, 959-969.

Westergard L, Christensen HM, Harris DA. 2007. The cellular prion protein (PrPC): Its physiological function and role in disease. Biochim. Biophys. Acta. Doi: 10 1016/ibbadis 2007 02 011.

Wong BS, Liu T, Li R, Pan T, Petersen RB, Smith MA, Gambetti P, Perry G, Manson JC,Brown DR, Sy MS. 2001. Increased levels of oxidative stress markers detected in the brains of mice devoid of prion protein. J Neurochem 76, 565-572.

Zanata SM, Lopes MH, Mercadante AF, Hajj GN, Chiarini LB, Nomizo R, Freitas AR, Cabral AL, Lee KS, Juliano MA, de Oliveira E, Jachieri SG, Burlingame A, Huang L, Linden R, Brentani RR, Martins VR. 2002. Stress-inducible protein 1 is a cell surface ligand for cellular prion that triggers neuroprotection EMBO J 21, 3307-3316.

Zhang CC, Steele AD, Lindquist S, Lodish HF. 2006. Prion protein is expressed on long-term repopulating hematopoietic stem cells and is important for their self-renewal. Proc Natl Acad Sci USA 103, 3416-3421.

Zou WQ, Zheng J, Gray DM, Gambetti P, Chen SG. 2004. Antibody to DNA detects scrapie but not normal prion protein. Proc Natl Acad Sci USA 101, 1380-1385.